|
In
their never-ending quest to find "magic bullets", pharmaceutical
companies are now setting their sites on creating anti-aging medicines,
attempting to turn back the hands of time and reverse damage already done.
One of the ways in which they are attempting
to do so is to attack and break-up stiff sugar-protein bonds known as
advanced glycation end products (AGEs). These substances are formed when
blood sugar (glucose) attaches itself to proteins in the body's tissues,
becoming cross-linked into hard yellow-brown AGE compounds.
This theory concerning the relationship
between sugar and the aging process goes back many years and is based
upon the observation of diabetics, who seem to age rapidly. When glucose
bonds with collagen, this can result in many negative effects, including
thickened arteries, stiff joints, feeble muscles and failing organs.
Diabetics age prematurely because this
sugar-driven damage acquires breakneck speed, raising their levels of
AGE-infused collagen to those of elderly people. Diabetics suffer a very
high incidence of nerve, artery and kidney damage because high blood sugar
levels in their bodies markedly accelerate the chemical reactions that
form advanced glycation products.
According to this report in Scientific
American, "after years of bread, noodles and cakes, human tissues
inevitably become rigid and yellow with pigmented AGE deposits."
Food chemists in the early part of this
century discovered that adding sulfites prevents browning and hardening
and keeps food and beverages looking fresh. This is the theory with which
the drug companies are now attempting to stop the production of AGEs by
developing a drug that may actually reverse the aging process by cracking
sugar-protein links once they form.
"Instead of looking for prevention,
we can now administer a compound to reduce the stiffness we see in diabetes
and aging," a researcher reported at a recent Novartis Foundation
symposium in London. The drug, dubbed ALT-711, can supposedly tear tough
AGE bonds apart.
Diabetic animals, old dogs and elderly
rhesus monkeys given the compound daily for three weeks yielded positive
results, with improvements seen in the heart and major arteries, which
became more pliable and elastic.
Researchers see other applications for
these new drugs as well. For example, in glaucoma, increasing the elasticity
of the draining canal of the eye would prevent the buildup of pressure
in the eye. Additionally, lung elasticity could be improved and an enlarged
and hardened prostate could be softened if the new research pans out.
But it will be at least 10 years until such drugs, currently undergoing
clinical trials, are approved for humans.
Scientific American
July 2000, page 16
|